People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses

BACKGROUND: Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial responses to a third dose. METHODS: We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapointe, Hope R., Mwimanzi, Francis, Cheung, Peter K., Sang, Yurou, Yaseen, Fatima, Umviligihozo, Gisele, Kalikawe, Rebecca, Speckmaier, Sarah, Moran-Garcia, Nadia, Datwani, Sneha, Duncan, Maggie C., Agafitei, Olga, Ennis, Siobhan, Young, Landon, Ali, Hesham, Ganase, Bruce, Omondi, F. Harrison, Dong, Winnie, Toy, Junine, Sereda, Paul, Burns, Laura, Costiniuk, Cecilia T., Cooper, Curtis, Anis, Aslam H., Leung, Victor, Holmes, Daniel, DeMarco, Mari L., Simons, Janet, Hedgcock, Malcolm, Prystajecky, Natalie, Lowe, Christopher F., Pantophlet, Ralph, Romney, Marc G., Barrios, Rolando, Guillemi, Silvia, Brumme, Chanson J., Montaner, Julio S.G., Hull, Mark, Harris, Marianne, Niikura, Masahiro, Brockman, Mark A., Brumme, Zabrina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963693/
https://www.ncbi.nlm.nih.gov/pubmed/35350205
http://dx.doi.org/10.1101/2022.03.22.22272793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963693/
https://www.ncbi.nlm.nih.gov/pubmed/35350205
http://dx.doi.org/10.1101/2022.03.22.22272793

Ejemplares similares